Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H16F2N8O2 |
Molecular Weight | 426.3795 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=CC=CC=C3F)C4=NC=C(F)C=C24
InChI
InChIKey=QZFHIXARHDBPBY-UHFFFAOYSA-N
InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27)
Molecular Formula | C19H16F2N8O2 |
Molecular Weight | 426.3795 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2111348 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28557445 |
1005.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02861534
Starting dose of 2.5 mg taken orally once daily with food, on a background of standard of care. Dose will be uptitrated to 5 mg and to 10 mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28557445
Studies on the in
vitro effects of Vericiguat on highly purified sGC (soluble guanylate cyclase) revealed that Vericiguat (0.01
uM to 100 uM) stimulates recombinant sGC concentration
dependently, by 1.7-fold to 57.6-fold.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 17 21:39:16 UTC 2022
by
admin
on
Sat Dec 17 21:39:16 UTC 2022
|
Record UNII |
LV66ADM269
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
LV66ADM269
Created by
admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
|
PRIMARY | |||
|
Vericiguat
Created by
admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
|
PRIMARY | |||
|
142432
Created by
admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
|
PRIMARY | |||
|
9805
Created by
admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
|
PRIMARY | |||
|
DB15456
Created by
admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
|
PRIMARY | |||
|
LV66ADM269
Created by
admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
|
PRIMARY | |||
|
C152862
Created by
admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
|
PRIMARY | |||
|
1350653-20-1
Created by
admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
|
PRIMARY | |||
|
54674461
Created by
admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
|
PRIMARY | |||
|
2475830
Created by
admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
|
PRIMARY | |||
|
GH-146
Created by
admin on Sat Dec 17 21:39:17 UTC 2022 , Edited by admin on Sat Dec 17 21:39:17 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
BINDER->LIGAND |
Protein binding (primarily to serum albumin) of vericiguat is about 98%.
BINDING
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
TARGET -> ACTIVATOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
IN HEALTHY SUBJECTS PHARMACOKINETIC |
|
||
Tmax | PHARMACOKINETIC |
|
FASTED STATE PHARMACOKINETIC |
|
||
ABSOLUTE BIOAVAILABILITY | PHARMACOKINETIC |
|
FED CONDITION PHARMACOKINETIC |
|
||
Biological Half-life | PHARMACOKINETIC |
|
IN PATIENTS WITH HEART FAILURE NUCLEIC ACID FEATURE |
|
||
Tmax | PHARMACOKINETIC |
|
HIGH-FAT, HIGH-CALORIE MEAL PHARMACOKINETIC |
|
||